Recently, we were able to demonstrate significant preclinical activity of a dual HER2 and EGFR kinase inhibitor in endometrial cancer cell lines with HER2 amplification or EGFR expression (Konecny et al, 2008). Here, EGFR is linked to endometrial cancer.